3 High-Flying Stocks That Could Soar Even More in 2025
And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...
2minutemedicine.com6d
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...